Successful use of narsoplimab to treat allogeneic transplant-associated thrombotic microangiopathy while maintaining sirolimus

Mohammad Alhomoud,Michael Scordo,Miguel-Angel Perales

DOI: https://doi.org/10.1038/s41409-024-02263-w

2024-03-12

Bone Marrow Transplantation

Abstract:Hematopoietic cell transplantation-associated thrombotic microangiopathy (TA-TMA) is a unique thrombotic and inflammatory disorder that complicates the post allogeneic hematopoietic cell transplantation (alloHCT) course in up to15% of patients [1, 2], leading to a significant increase in morbidity and mortality [3]. TA-TMA has a median time-to-onset of 86 days post alloHCT [4]. Endothelial injury is the key event for TA-TMA, with subsequent endothelial cell injury propagating pro-inflammatory cytokines leading to activation of both alternative and lectin pathways of complement [5, 6]. Hemolytic anemia leading to longer-than-expected transfusion needs, thrombocytopenia and wide range of organ dysfunction characterize TA-TMA [2]. The historic lack of uniformly accepted clinical diagnostic criteria and the fact TA-TMA often coincides with other confounding complications post alloHCT that share common manifestations makes the diagnosis challenging. Efforts to build a consensus definition for TA-TMA by multiple societies have been recently published [7]. Graft-versus-host disease (GVHD) itself and the drugs typically used for prophylaxis such as calcineurin inhibitors (CNI) or mammalian target of rapamycin (mTOR) inhibitors, are often implicated in potentiating TA-TMA and complicating its diagnosis and management [8]. A growing body of evidence suggests that preexisting or novel endothelial dysfunction may create the necessary immune-inflammatory environment for TA-TMA, a process that can be exacerbated by GVHD [9, 10]. CNI cause endotheliopathy by their direct cytotoxic damage, elevated thrombomodulin and decreased prostacyclin, while mTOR inhibitors prevent endothelial repair and decrease VEGF production [11]. Withdrawal of CNI and/or mTOR inhibitors upon identifying TA-TMA has been commonly practiced as a primary intervention [12]. However, since TA-TMA can occur early in post alloHCT and/or with concomitant active GVHD, this approach can be challenging. The use of anti-C5 monoclonal antibody eculizumab has shown promising activity in pediatric patients with TA-TMA, resulting in 66% overall survival (OS) at 1 year (compared to 16.7% in control) [13]. In adult patients with TA-TMA, small retrospective studies have reported hematological responses with eculizumab in most patients, however, with limited OS benefit, with only one third of patients alive at 30 weeks post TA-TMA diagnosis [14]. Narsoplimab (Omeros Corporation, Seattle, WA) is a novel, fully human immunoglobulin G4 monoclonal antibody that inhibits mannan-binding lectin-associated serine protease-2 (MASP2), the effector enzyme of the lectin pathway of complement. A recent phase II study evaluated the efficacy of narsoplimab prospectively in 28 patients with high-risk TA-TMA showed promising results with 61% response rate (defined as improvement in both TA-TMA markers and organ dysfunction) and 68% OS at 100 days from the date of TA-TMA diagnosis [15]. Herein, we report for the first time, a patient with high-risk TA-TMA successfully treated with narsoplimab while maintaining GVHD prophylaxis/treatment.

oncology,immunology,hematology,transplantation